Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Alnylam shares tank 29% as Amvuttra disappoints with ATTR outlook cut for 2026
Alnylam Pharmaceuticals’ stock price plummeted as much as 29% Thursday morning after disappointing Amvuttra sales and a lowered full-y | Alnylam’s stock price plummeted as much as 29% Thursday morning after disappointing Amvuttra sales and a lowered full-year forecast triggered fresh concerns over the ATTR franchise.
TL;DRAI
Alnylam's Amvuttra missed Q2 targets ($1.01B vs $1.05B expected), sparking a 29% stock drop and a $200M guidance cut. Competitive moats are widening as AstraZeneca's rival failed trials, but execution risk persists in reaching first-line market share targets.
578 words~3 min read
